ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

EVOTAZ
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

EVOTAZ Rx

Generic Name and Formulations:
Atazanavir 300mg, cobicistat 150mg; tabs.

Company:
Bristol-Myers Squibb

Therapeutic Use:

Indications for EVOTAZ:

HIV-1 infection in combination with other antiretroviral agents.

Limitations Of use:

Use in treatment-experienced patients should be guided by number of baseline primary protease inhibitor resistance substitutions.

Adult:

Take with food. 1 tab daily.

Children:

<18yrs: not established.

Contraindications:

Concomitant alfuzosin, ranolazine, dronedarone, carbamazepine, phenobarbital, phenytoin, colchicine (in renal/hepatic impaired), rifampin, irinotecan, lurasidone, pimozide, triazolam, oral midazolam, ergots, cisapride, elbasvir/grazoprevir, St. John's wort, lovastatin, simvastatin, nevirapine, sildenafil (for PAH), indinavir.

Warnings/Precautions:

Assess CrCl prior to initiation. Concomitant tenofovir DF: assess baseline CrCl, urine glucose, and urine protein; if CrCl <70mL/min: not recommended; monitor serum phosphorous if risk of renal impairment. ESRD with hemodialysis in treatment-experienced or hepatic impairment: not recommended. Cardiac conduction abnormalities; consider ECG monitoring if preexisting marked 1st -degree AV block or 2nd/3rd -degree AV block. Consider interruption or discontinuation if nephrolithiasis or cholelithiasis occurs. Hepatitis B and/or C or marked elevations in transaminases: monitor LFTs before and during therapy. Consider alternative if jaundice or scleral icterus occurs. Diabetes. Hemophilia. Elderly. Pregnancy. Nursing mothers: not recommended.

Interactions:

See Contra­in­di­ca­tions. Separate dosing with concomitant H2 receptor antagonists, PPIs (not recommended in treatment-experienced), antacids, enteric-coated didanosine. Concomitant tenofovir DF with concomitant or recent nephrotoxic agents, other antiretrovirals that require CYP3A inhibition (eg, HIV protease inhibitors, elvitegravir), ritonavir or ritonavir-containing products, CYP2C8 substrates with narrow therapeutic indices (eg, paclitaxel, repaglinide), efavirenz, etravirine, boceprevir, simeprevir, apixaban, rivaroxaban, dabigatran etexilate, avanafil, inhaled/nasal steroids, salmeterol, voriconazole: not recommended. May need to adjust dose of insulin, antidiabetics, dasatinib, nilotinib, sildenafil, tadalafil, vardenafil, perphenazine, risperidone, thioridazine, buprenorphine, naloxone, methadone, tramadol, bosentan, rifabutin, and sedatives/hypnotics. Concomitant maraviroc: give maraviroc 150mg twice daily. Potentiates quetiapine: consider alternative antiretrovirals; if coadministration necessary, reduce quetiapine to ⅙ of current dose and monitor. Monitor concomitant antiarrhythmics, digoxin, vincristine, vinblastine, warfarin, clonazepam, lamotrigine, SSRIs, TCAs, trazodone, fentanyl, immunosuppressants, other statins, β-blockers, CCBs. Concomitant clarithromycin, erythromycin, telithromycin, CYP3A-inducing anticonvulsants (eg, eslicarbazepine, oxcarbazepine), systemic corticosteroids (eg, dexamethasone): consider alternatives. See full labeling.

Pharmacological Class:

HIV-1 protease inhibitor + CYP3A inhibitor.

Adverse Reactions:

Jaundice, rash (may be severe; discontinue if occurs), ocular icterus; hyperbilirubinemia, fat redistribution, immune reconstitution syndrome.

Generic Availability:

NO

How Supplied:

Tabs—30

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs